Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, autoimmune encephalitis, chronic inflammatory demyelinating polyradiculoneuropathy, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, neuromyelitis optica, optic nerve disorder, optic neuritis, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy	Recruiting	Early phase 1	2025-12-15		NCT06939166

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanghai Xiniao Biotech Co., Ltd.	8
Tianjin Huanhu Hospital	27

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Tianjin Huanhu Hospital	Tianjin	China	6